Ameriprise
RPRX icon

Ameriprise’s Royalty Pharma RPRX Stock Holding History

Ameriprise’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9M Sell
461,447
-115,678
-20% -$6.02M 0.01% 1349
2026
Q1 		$27.7M Buy
577,125
+35,086
+6% +$1.54M 0.01% 1197
2025
Q4 		$20.9M Buy
542,039
+131,965
+32% +$5.03M ﹤0.01% 1386
2025
Q3 		$14.5M Buy
410,074
+239,346
+140% +$8.66M ﹤0.01% 1633
2025
Q2 		$6.15M Buy
170,728
+148,752
+677% +$4.93M ﹤0.01% 2208
2025
Q1 		$684K Sell
21,976
-2,256
-9% -$71.5K ﹤0.01% 3374
2024
Q4 		$618K Sell
24,232
-23,786
-50% -$631K ﹤0.01% 3443
2024
Q3 		$1.36M Buy
48,018
+3,024
+7% +$83.8K ﹤0.01% 3089
2024
Q2 		$1.19M Sell
44,994
-132,364
-75% -$3.67M ﹤0.01% 3088
2024
Q1 		$5.39M Buy
177,358
+10,806
+6% +$319K ﹤0.01% 2313
2023
Q4 		$4.68M Sell
166,552
-2,271,500
-93% -$62.4M ﹤0.01% 2394
2023
Q3 		$66.2M Buy
2,438,052
+229,165
+10% +$6.81M 0.02% 640
2023
Q2 		$67.9M Buy
2,208,887
+723,451
+49% +$24.5M 0.02% 635
2023
Q1 		$53.5M Buy
1,485,436
+98,288
+7% +$3.64M 0.02% 724
2022
Q4 		$54.8M Buy
1,387,148
+12,907
+0.9% +$539K 0.02% 688
2022
Q3 		$55.2M Buy
1,374,241
+84,542
+7% +$3.61M 0.02% 663
2022
Q2 		$54.2M Sell
1,289,699
-2,418
-0.2% -$99.1K 0.02% 686
2022
Q1 		$50.3M Sell
1,292,117
-8,554
-0.7% -$336K 0.01% 810
2021
Q4 		$51.8M Buy
1,300,671
+8,410
+0.7% +$327K 0.01% 825
2021
Q3 		$46.7M Sell
1,292,261
-59,915
-4% -$2.33M 0.01% 799
2021
Q2 		$55.4M Buy
1,352,176
+88,292
+7% +$3.76M 0.02% 749
2021
Q1 		$55.2M Buy
1,263,884
+471,201
+59% +$22.3M 0.02% 730
2020
Q4 		$39.7M Buy
792,683
+171,965
+28% +$7.3M 0.01% 855
2020
Q3 		$26.1M Sell
620,718
-804,652
-56% -$34.5M 0.01% 937
2020
Q2 		$69.2M Buy
+1,425,370
New +$70.6M 0.03% 501

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise's RPRX Position: Q2 2026 in Review

Ameriprise reduced its Royalty Pharma (RPRX) stake by 20% in Q2 2026, selling an estimated $6.02M and leaving 461,447 shares worth $25.9M. The position accounts for 0.01% of the portfolio, ranked #1349.

Ameriprise first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. The position peaked at $69.2M in Q2 2020. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Ameriprise held 461,447 shares of Royalty Pharma worth $25.9M as of Q2 2026.
  • Ameriprise sold 115,678 Royalty Pharma shares in Q2 2026, an estimated $6.02M.
  • Royalty Pharma made up 0.01% of Ameriprise's portfolio in Q2 2026, its #1349 holding.
  • Ameriprise first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • Ameriprise's Royalty Pharma position peaked at $69.2M in Q2 2020.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.